Doses in organs at risk during head and neck radiotherapy using IMRT and 3D-CRT
Open Access
|Nov 2012References
- 1. Gabrys D, Wesolowska I, Suwinski R. The evaluation of 3DRT and IMRT techniques in postoperative radiotherapy for thyroid medullary carcinoma.2008;126-9.
- 2. Miften MM, Das SK, Su M, Marks LB. A dose-volume-based tool for evaluating and ranking IMRT treatment plans2004;1-14.
- 3. Trojanowska A. Squamous cell carcinoma of the head and neck-The role of diffusion and perfusion imaging in tumor recurrence and follow-up.2011;203-8.
- 4. Buettner F, Miah AB, Gulliford SL, Hall E, Harrington KJ, Webb S, et al. Novel approaches to improve the therapeutic index of head and neck radiotherapy: An analysis of data from the PARSPORT randomised phase III trial.2012;82-7.
- 5. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. PARSPORT trial management group. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.2011;127-36.
- 6. Binhu J, Supe S, Pawar Y. Intensity modulated radiotherapy (IMRT) the white, black and grey: a clinical perspective.2009;95-103.
- 7. Rosenthal DI, Chambers MS, Fuller CD, Rebueno NCS, Garcia J, Kies MS, et al. Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer.2008;747-55.
- 8. Sas-Korczyńska B, Śladowska A, Rozwadowska-Bogusz B, Dyczek S, Lesiak J, Kokoszka A, et al. Comparison between intensity modulated radiotherapy (IMRT) and 3D tangential beams technique used in patients with early-stage breast cancer who received breast-conserving therapy.2010;79-86.
- 9. Lee N, Puri DR, Blanco AI, Chao KSC. Intensity modulated radiation therapy in head and neck cancers: An update.2007;387-400.
- 10. Bhide SA, Nutting CM. Advances in radiotherapy for head and neck cancer.2010;439-41.
- 11. Clark CH, Hansen VN, Chantler H, Edwards C, James HV, Webster G, et al. Dosimetry audit for a multi-centre IMRT head and neck trial.2009;102-8.
- 12. Tribius S, Bergelt C. Intensity-modulated radiotherapy versus conventional and 3D conformal radiotherapy in patients with head and neck cancer: Is there a worthwhile quality of life gain?2011;511-9.
- 13. Piotrowski T, Martenka P, De Patoul N, Jodda A, Coevoet M, Malicki J, et al. The new two-component conformity index formula (TCCI) and dose-volume comparisons of the pituitary gland and tonsil cancer IMRT plans using a linear accelerator and helical tomotherapy.2009;133-45.
- 14. Grzadziel A, Grosu A, Kneschaurek P. Three-dimensional conformal versus intensity-modulated radiotherapy dose planning in stereotactic radiotherapy: Application of standard quality parameters for plan evaluation.2006;S87-94.
- 15. Pesznyak C, Polgar I, Weisz C, Kiraly R, Zarand P. Verification of quality parameters for portal image in radiotherapy.2011;66-74.
- 16. Bailey DW, Kumaraswamy L, Podgorsak MB. A Fully electronic intensitymodulated radiation therapy quality assurance (IMRT QA) process implemented in a network comprised of independent treatment planning, record and verify, and delivery systems.2010;124-30.
- 17. Mendenhall W, Mancuso A. Radiotherapy for head and neck cancer - is the “next level” down?2009;645-6.
- 18. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, Rosen II. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy2005;1195-203.
- 19. Howell RM, Scarboro SB, Kry SF, Yaldo DZ. Accuracy of out-ofi-field dose calculations by a commercial treatment planning system.2010;6999-7008.
- 20. Prescribing, Recording, and Reporting Photon Beam Therapy (Report 50), ICRU Report No. 50; 1993.
- 21. Prescribing, Recording and Reporting Photon Beam Therapy (Report 62), (Supplement to ICRU Report 50), ICRU Report 62; 1999.
- 22. Reference Data for the Validation of Doses from Cosmic-Radiation Exposure of Aircraft Crew (ICRU 84), ICRU Report 84.2012;
- 23. Hall E, Wuu C. Radiation-induced second cancers: the impact of 3D-CRT and IMRT1.2003;83-8.
- 24. Dorr W, Stewart FA. Retreatment tolerance of normal Tissues. In:Joiner M and van der Kogel A, editors. 4th Edition. London: Hodder Arnold; 2009. p. 259-90.
- 25. Marks LB, Yorke ED, Jackson A, Ten Haken RT, Comstine LS, Eisbruch A, et al. Use of normal tissue complication probability models in the clinic.2010;S10-9.
- 26. Kupchak C, Battista J, Van Dyk J. Experience-driven dose-volume histogram maps of NTCP risk as an aid for radiation treatment plan selection and optimization.2008;333-43.
- 27. Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls.2006;2618 -23.
- 28. Chen AM, Hall WH, Li B-Q, Guiou M, Wright C, Mathai M, et al. Intensitymodulated radiotherapy increases dose to the brachial plexus compared with conventional radiotherapy for head and neck cancer.2011;58-63.
- 29. Longobardi B, De Martin E, Fiorino C, Delloca I, Broggi S, Cattaneo GM, et al. Comparing 3DCRT and inversely optimized IMRT planning for head and neck cancer: Equivalence between step-and-shoot and sliding window techniques.2005;148-56.
- 30. Winiecki J, Zurawski Z, Drzewiecka B, Slosarek K. Anatomy-corresponding method of IMRT verification.2011;1-9.
- 31. Malicki J., Litoborski M, Kierzkowski J, Kosicka G. How the implementation of an in-vivo dosimetry protocol improved the dose delivery accuracy in head and neck radiotherapy.2004;155-8.
- 32. Knöös T, Kristensen I, Nilsson P. Volumetric and dosimetric evaluation of radiation treatment plans: radiation conformity index.1998;1169-76.
- 33. Clark CH, Miles EA, Urbano MTG, Bhide SA, Bidmead AM, Harrington KJ, et al. Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer.2009;585-94.
- 34. Guerrero Urbano MT, Clark CH, Kong C, Miles E, Dearnaley DP, Harrington KJ, et al. Target volume definition for head and neck intensity modulated radiotherapy: Pre-clinical evaluation of PARSPORT trial guidelines.2007;604-13.
- 35. Gizynska M, Zawadzka A. IMRT versus 3D-CRT for thyroid cancer.2008;151-62.
- 36. Malicki J. The importance of accurate treatment planning, delivery, and dose verification.2012;63-5.
Language: English
Page range: 328 - 336
Submitted on: Jun 17, 2012
Accepted on: Sep 17, 2012
Published on: Nov 9, 2012
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2012 Magdalena Peszynska-Piorun, Julian Malicki, Wojciech Golusinski, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.